Company intelligence / Profile preview

Javelin Biotech

Woburn, Massachusetts, United Statesjavelinbiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Javelin Biotech has developed a commercial-stage predictive drug discovery platform that merges human tissue chips with computational biology/machine learning. Their first product—a pharmacokinetics prediction platform—was developed in partnership with Pfizer and delivers clinical predictions that are 33% more accurate and 10x faster than traditional rat PK studies. The company’s technology aims to reduce reliance on animal models in preclinical R&D.

Therapeutic areas: Metabolic DisordersNeurologyOther
Modalities: Small moleculesmRNA-based drugsGene therapies
Industry: Drug Discovery Services

Partnerships

Pfizer (collaboration to develop organ-on-a-chip ADME/PK prediction platform)

Beyond the preview

Go deeper on Javelin Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Javelin Biotech.

Explore the full profile